We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis.
- Authors
Vališ, Martin; Achiron, Anat; Hartung, Hans Peter; Mareš, Jan; Tichá, Veronika; Štourač, Pavel; Halusková, Simona; Angelucci, Francesco; Pavelek, Zbyšek
- Abstract
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing–remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS.
- Subjects
EUROPEAN Medicines Agency; UNITED States. Food &; Drug Administration; MULTIPLE sclerosis; DISEASE relapse; CENTRAL nervous system; NEURODEGENERATION; MEDICAL personnel; FINGOLIMOD; INTERFERON beta 1b
- Publication
Drugs in R&D, 2023, Vol 23, Issue 4, p331
- ISSN
1174-5886
- Publication type
Article
- DOI
10.1007/s40268-023-00434-6